Calprotectin in rheumatic diseases: a review.

Reumatologia

Department of Internal Medicine and Rheumatology, Katowice, Poland.

Published: December 2016

Calprotectin also known as MRP8/14 or S100A8/A9 is a heterodimeric complex of two S100 calcium-binding proteins: myeloid-related protein 8 (MRP-8 or S100A8) and MRP-14 (or S100A9). At present, according to many authors, it is considered that calprotectin MRP8/14 is a potentially more sensitive biomarker of disease activity in rheumatoid disease than conventional inflammatory indices such as the erythrocyte sedimentation rate, C-reactive protein and others. A review of the literature on concentration of calprotectin in patients with some rheumatic diseases (rheumatoid arthritis, juvenile idiopathic arthritis, adult-onset Still's disease, systemic vasculitis, polymyalgia rheumatica, ankylosis spondylitis, systemic lupus erythematosus, and primary Sjögren's syndrome) is presented.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241367PMC
http://dx.doi.org/10.5114/reum.2016.64907DOI Listing

Publication Analysis

Top Keywords

rheumatic diseases
8
calprotectin mrp8/14
8
calprotectin
4
calprotectin rheumatic
4
diseases review
4
review calprotectin
4
mrp8/14 s100a8/a9
4
s100a8/a9 heterodimeric
4
heterodimeric complex
4
complex s100
4

Similar Publications

Objective: To evaluate the adoption, effectiveness and cost-effectiveness of digital health interventions for rheumatic disease management.

Methods: Between 25 May 2024 and 2 June 2024, we systematically searched PubMed®, Scopus, ClinicalTrials.gov, the Global Observatory for eHealth and the World Bank Open Knowledge Repository for randomized controlled trials (RCTs) evaluating digital health interventions for rheumatic disease management.

View Article and Find Full Text PDF

[Rheumatology: what's new in 2024].

Rev Med Suisse

January 2025

Service de rhumatologie, HFR Fribourg, 1708 Fribourg.

In 2024, CD19-CAR T cells are ubiquitous in rheumatology, with incredible therapeutic results in cases of severe and refractory disease. This major advance confirms the interest of the B lymphocyte as a therapeutic target, and also suggests the real possibility of a drug-free remission, at the price of minor and minimal side effects for the time being. However, the necessary perspective is still lacking for a therapy that remains out of reach because of its price.

View Article and Find Full Text PDF

Background And Purpose:  The introduction and development of new total knee arthroplasty (TKA) implant designs are industry driven. To date, an adequately powered randomized controlled trial (RCT) to provide evidence of the superiority of novel implant designs over conventional ones is often lacking. The aim of our RCT was to investigate the functional outcomes of a novel TKA implant design compared with 2 conventional TKA designs.

View Article and Find Full Text PDF

Objective: The objective of this study was to explore the ability of dual-energy computed tomography (DECT) to detect monosodium urate (MSU) crystal deposits in the kidneys and renal artery walls, and uric acid urolithiasis, in patients with gout and chronic kidney disease (CKD).

Methods: Patients with gout and with stage 2-4 CKD were prospectively included in this cross-sectional study. Patients underwent renal, knee and feet DECT scans.

View Article and Find Full Text PDF

Study Design: A systematic review and meta-analysis.

Objective: This study aimed to determine whether rheumatoid arthritis (RA) is associated with clinical outcomes following spinal surgery for lumbar spinal disorders.

Methods: MEDLINE, Embase, the Cochrane Library, and the International Clinical Trials Registry Platform were comprehensively searched for observational studies comparing clinical outcomes after lumbar spine surgery in patients with and without RA (>18 years).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!